{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:27:36Z","timestamp":1737696456609,"version":"3.33.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,23]]},"DOI":"10.7759\/cureus.77888","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:52:22Z","timestamp":1737679942000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes of Rituximab Infusion Among Refractory Myasthenia Gravis Patients in the Philippines: A 10-Year Retrospective Study"],"prefix":"10.7759","author":[{"given":"Alyssa Pauline C","family":"Co","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig F","family":"Damian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus NE","year":"2015","unstructured":"Gilhus NE,  Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015, 14:1023-36. 10.1016\/s1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0612- x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles G","year":"2017","unstructured":"Salles G, Barrett M, Foa R. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Therapy. 2017, 34:2232-73. 10.1007\/s12325-017-0612- x","journal-title":"Adv Therapy"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri NJ","year":"2014","unstructured":"Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromusc Dis. 2014, 15:167-78. 10.1097\/CND.0000000000000034","journal-title":"J Clin Neuromusc Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/sjopt.sjopt_74_23","article-title":"Eculizumab in myasthenia gravis: a review","volume":"38","author":"Zhou A","year":"2024","unstructured":"Zhou A, Ho S, Vickers A. Eculizumab in myasthenia gravis: a review. Saudi J Ophthalmol. 2024, 38:34-40. 10.4103\/sjopt.sjopt_74_23","journal-title":"Saudi J Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1275533","article-title":"Rituximab treatment in myasthenia gravis","volume":"14","author":"Vesperinas-Castro A","year":"2023","unstructured":"Vesperinas-Castro A, Cort\u00e9s-Vicente E. Rituximab treatment in myasthenia gravis. Front Neurol. 2023, 14:1275533. 10.3389\/fneur.2023.1275533","journal-title":"Front Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.12.004","article-title":"Resistant myasthenia gravis and rituximab: a monocentric retrospective study of 28 patients","volume":"27","author":"Afanasiev V","year":"2017","unstructured":"Afanasiev V, Demeret S, Bolgert F, Eymard B, Lafor\u00eat P, Benveniste O. Resistant myasthenia gravis and rituximab: a monocentric retrospective study of 28 patients. Neuromuscul Disord. 2017, 27:251-8. 10.1016\/j.nmd.2016.12.004","journal-title":"Neuromuscul Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of Rituximab for new-onset generalized myasthenia gravis: the Rinomax randomized clinical trial","volume":"79","author":"Piehl F","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A, et al.. Efficacy and safety of Rituximab for new-onset generalized myasthenia gravis: the Rinomax randomized clinical trial. JAMA Neurol. 2022, 79:1105-12. 10.1001\/jamaneurol.2022.2887","journal-title":"JAMA Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/0028-3886.359277","article-title":"Rituximab in myasthenia gravis- experience from a low- and middle-income country (LMIC) setting","volume":"70","author":"Shivaram S","year":"2022","unstructured":"Shivaram S, Nagappa M, Varghese N, et al.. Rituximab in myasthenia gravis- experience from a low- and middle-income country (LMIC) setting. Neurol India. 2022, 70:1931-41. 10.4103\/0028-3886.359277","journal-title":"Neurol India"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza R","year":"2018","unstructured":"Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018, 11:1756285617749134. 10.1177\/1756285617749134","journal-title":"Ther Adv Neurol Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19416","article-title":"Rituximab in the management of refractory myasthenia gravis and variability of its efficacy in Anti-MUSK positive and Anti-ACHR positive myasthenia gravis","volume":"13","author":"Bastakoti S","year":"2021","unstructured":"Bastakoti S, Kunwar S, Poudel S, et al.. Rituximab in the management of refractory myasthenia gravis and variability of its efficacy in Anti-MUSK positive and Anti-ACHR positive myasthenia gravis. Cureus. 2021, 13:e19416. 10.7759\/cureus.19416","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.736190","article-title":"Effectiveness and safety of Rituximab for refractory myasthenia gravis: a systematic review and single-arm meta-analysis","volume":"12","author":"Zhao C","year":"2021","unstructured":"Zhao C, Pu M, Chen D, Shi J, Li Z, Guo J, Zhang G. Effectiveness and safety of Rituximab for refractory myasthenia gravis: a systematic review and single-arm meta-analysis. Front Neurol. 2021, 12:736190. 10.3389\/fneur.2021.736190","journal-title":"Front Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2016.00096","article-title":"Clinical profile and outcome of postthymectomy versus non-thymectomy myasthenia gravis patients in the Philippine General Hospital: a 6-year retrospective study","volume":"7","author":"De Roxas RC","year":"2016","unstructured":"De Roxas RC, Bagnas MA, Baldonado JJ, Rivera JP, Roxas AA. Clinical profile and outcome of postthymectomy versus non-thymectomy myasthenia gravis patients in the Philippine General Hospital: a 6-year retrospective study. Front Neurol. 2016, 7:96. 10.3389\/fneur.2016.00096","journal-title":"Front Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results","volume":"58","author":"Beecher G","year":"2018","unstructured":"Beecher G, Anderson D, Siddiqi ZA. Rituximab in refractory myasthenia gravis: extended prospective study results. Muscle Nerve. 2018, 58:452-5. 10.1002\/mus.26156","journal-title":"Muscle Nerve"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/aian.aian_579_24","article-title":"Rituximab in refractory myasthenia gravis - challenges and lessons learnt","volume":"27","author":"Valaparambil KA","year":"2024","unstructured":"Valaparambil KA, Sundaram S, Nair SS. Rituximab in refractory myasthenia gravis - challenges and lessons learnt. Ann Indian Acad Neurol. 2024, 27:706-9. 10.4103\/aian.aian_579_24","journal-title":"Ann Indian Acad Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-328665","article-title":"Eculizumab versus rituximab in generalised myasthenia gravis","volume":"93","author":"Nelke C","year":"2022","unstructured":"Nelke C, Schroeter CB, Stascheit F, et al.. Eculizumab versus rituximab in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2022, 93:548-54. 10.1136\/jnnp-2021-328665","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals","volume":"82","author":"Menon D","year":"2022","unstructured":"Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022, 82:865-87. 10.1007\/s40265-022-01726-y","journal-title":"Drugs"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S377056","article-title":"Novel immunotherapies for myasthenia gravis","volume":"12","author":"Nair SS","year":"2023","unstructured":"Nair SS, Jacob S. Novel immunotherapies for myasthenia gravis. Immunotargets Ther. 2023, 12:25-45. 10.2147\/ITT.S377056","journal-title":"Immunotargets Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/337044-clinical-outcomes-of-rituximab-infusion-among-refractory-myasthenia-gravis-patients-in-the-philippines-a-10-year-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:52:23Z","timestamp":1737679943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/337044-clinical-outcomes-of-rituximab-infusion-among-refractory-myasthenia-gravis-patients-in-the-philippines-a-10-year-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.77888","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,23]]}}}